Name: Juvmo (tavapadon) in Parkinson's disease: Access and distribution
Published: 2026-09-27T21:44:59-04:00

Product information and disease description Product description Product information

Access and distribution

6 evidence topics · 5 sources

Marketer and trademark holder

“Marketed by: AbbVie Inc. North Chicago, IL 60064 U.S.A.” (opens the prescribing information at this quote)
“JUVMO and its design are trademarks of Cerevel Therapeutics, LLC, an AbbVie company.” (opens the prescribing information at this quote)

Package configurations and National Drug Codes

Presentation	Quoted package configuration	Quoted NDC
5 mg tablets	“Bottle of 30”	“0074-6105-30”
10 mg tablets	“Bottle of 30”	“0074-6210-30”
15 mg tablets	“Bottle of 30”	“0074-6315-30”
Titration pack (0.25 mg and 1 mg tablets)	“Each carton contains 6 weekly blister cards containing the following total number of tablets:”	“0074-6090-40”

Prescriber website before launch

“Get ready for something new from AbbVie Inc.” (opens the source at this quote in a new tab)
“Learn more right at launch about JUVMO and stay current with product updates when you sign up below.” (opens the source at this quote in a new tab)

Expanded access program

“This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to tavapadon prior to approval by the local regulatory agency. Availability will depend on territory eligibility.” (opens the source at this quote in a new tab)

Patent protection

“For tavapadon, the applicable patents and pending patent applications are directed to tavapadon, compositions of matter and certain methods of treatment, including methods of treating Parkinson’s disease and apathy in Alzheimer’s disease, and, excluding any patent term adjustments or extensions, have a statutory expiration date in 2034.” (opens the source at this quote in a new tab)

Security interest held by development funding investors

“In conjunction with the funding agreements, AbbVie also assumed security agreements entered into by Cerevel Therapeutics prior to the acquisition pursuant to which Cerevel Therapeutics granted the funding investors a security interest in the assets material to the development and commercialization of tavapadon in the United States.” (opens the source at this quote in a new tab)